Brown Advisory’s Capricor Therapeutics CAPR Stock Holding History

Brown Advisory’s Portfolio CAPR Stock Details CAPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-20,692	Closed	-$69K	–	1012
2019 Q2	$69K	Sell	20,692 -64,565	-76%	-$270K	﹤0.01%	1006
2019 Q1	$398K	Hold	85,257	–	–	﹤0.01%	1048
2018 Q4	$350K	Sell	85,257 -7,109	-8%	-$56.5K	﹤0.01%	1031
2018 Q3	$970K	Sell	92,366 -21,310	-19%	-$254K	﹤0.01%	816
2018 Q2	$1.52M	Hold	113,676	–	–	﹤0.01%	685
2018 Q1	$1.55M	Hold	113,676	–	–	0.01%	562
2017 Q4	$1.8M	Buy	+113,676	New	+$2.46M	0.01%	549
2017 Q1	–	Sell	-7,107	Closed	-$189K	–	1163
2016 Q4	$189K	Hold	7,107	–	–	﹤0.01%	1089
2016 Q3	$230K	Hold	7,107	–	–	﹤0.01%	960
2016 Q2	$281K	Hold	7,107	–	–	﹤0.01%	874
2016 Q1	$181K	Buy	+7,107	New	+$172K	﹤0.01%	940

Other funds holding CAPR

Royal London Asset Management United Kingdom $47.7B AUM 29.41% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

IAA

Independent Advisor Alliance Charlotte, North Carolina $9.32B AUM 33.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CBA

Coastal Bridge Advisors Westport, Connecticut $1.41B AUM 24.15% 1-Year Est. Return

US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Brown Advisory's CAPR Position: Q3 2019 in Review

Brown Advisory sold out of Capricor Therapeutics (CAPR) in Q3 2019, closing a stake of 20,692 shares — an estimated $69K sold.

Brown Advisory first reported a position in CAPR in Q1 2016 and held it in 11 quarters. The position peaked at $1.8M in Q4 2017. 16 funds tracked by Wall St. Rank hold CAPR as of Q3 2019.

Brown Advisory reported no remaining Capricor Therapeutics position as of Q3 2019 after selling out during the quarter.
Brown Advisory sold 20,692 Capricor Therapeutics shares in Q3 2019, an estimated $69K.
Brown Advisory first reported a position in Capricor Therapeutics in Q1 2016 and held it in 11 quarters.
Brown Advisory's Capricor Therapeutics position peaked at $1.8M in Q4 2017.
16 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q3 2019.

Based on Brown Advisory's 13F filing for Q3 2019, filed 14 Nov 2019.